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ABSTRACT 16 
A series of case studies designed to further acceptance of read-across predictions, especially 17 
for chronic health-related endpoints, have been evaluated with regard to the knowledge and 18 
insight they provide. A common aim of these case studies was to examine sources of 19 
uncertainty associated with read-across. While uncertainty is related to the quality and 20 
quantity of the read across endpoint data, uncertainty also includes a variety of other factors, 21 
the foremost of which is uncertainty associated with the justification of similarity and 22 
quantity and quality of data for the source chemical(s). This investigation has demonstrated 23 
that the assessment of uncertainty associated with a similarity justification includes 24 
consideration of the information supporting the scientific arguments and the data associated 25 
with the chemical, toxicokinetic and toxicodynamic similarity. Similarity in chemistry is 26 
often not enough to justify fully a read-across prediction, thus, for chronic health endpoints, 27 
toxicokinetic and/or toxicodynamic similarity is essential. Data from New Approach 28 
Methodology(ies) including high throughput screening, in vitro and in chemico assay and in 29 
silico tools, may provide critical information needed to strengthen the toxicodynamic 30 
similarity rationale. In addition, it was shown that toxicokinetic (i.e., ADME) similarity, 31 
especially metabolism, is often the driver of the overall uncertainty.  32 
 33 
Keywords: read-across; similarity; uncertainty; case studies; repeated-dose toxicity; 34 
regulatory acceptance. 35 
  36 
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Highlights: 37 
 Read-across case studies for repeated-dose toxicity were evaluated 38 
 Identification and definition of uncertainties in read-across is crucial 39 
 The logic and data leading to a read-across prediction must be documented  40 
 The similarity rationale of a read-across should be described transparently  41 
 The roles of any endpoint specific and/or non-specific factors should be clarified  42 
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1. Introduction 43 
Legislative requirements for the registration and safety assessment of chemicals, along with 44 
the need to obtain toxicological information without resorting to animal testing, have 45 
stimulated a more critical examination of read-across (RA). The concept of category 46 
formation, chemical grouping and RA is used to support chemical safety assessment by 47 
filling data gaps without the need for further in vivo testing (ECHA, 2014; OECD, 2014a; 48 
Stanton and Kruszewski, 2016). Historically, the fundamental assumptions of RA are that 49 
chemicals, which are similar in their structure, will have similar chemical properties and, 50 
thereby, have similar toxicokinetic and toxicodynamic properties (Cronin et al., 2013). A 51 
group of substances with similar toxicokinetic and toxicodynamic properties can be 52 
considered a toxicological meaningful category or a group of chemicals whose human health 53 
and/or environmental toxicological properties are likely to be similar or follow a regular 54 
pattern for a particular hazard. RA of toxic potencies based on such a category is a valuable 55 
approach to data gap filling, thus having a number of regulatory applications. Briefly, 56 
experimentally-derived toxicological properties from one or more source chemicals may be 57 
read across to fill the data gap for a target chemical, which is “similar” and for which an 58 
experimentally derived toxicological value is wanting and such prediction can be used for 59 
screening, priority setting, hazard assessment or risk assessment (Patlewicz and Fitzpatrick, 60 
2016). 61 
1.1. Background 62 
Since the review of Cronin et al (2013), a number of papers have appeared that focus on 63 
modern-day RA. Many of these, including Blackburn and Stuard (2014), European 64 
Chemicals Agency (ECHA) (2015), Organisation for Economic Co-operation and 65 
Development (OECD) (2015) and Schultz et al. (2015), have put forward efforts to improve 66 
RA arguments and improve and innovate approaches (Batke et al., 2016; de Abrew et al., 67 
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2016; Shah et al., 2016; van Ravenzwaay et al., 2016). More recently, Ball et al., (2016) 68 
summarised the state-of-the-art surrounding read-across, along with reasons relating to 69 
regulatory non-acceptance, and compiled relevant guidance under the heading of “Good 70 
Read-Across Practice”; Hartung (2016) described the concept of linking different types of 71 
data and tools under the umbrella of good read-across practices.  72 
It is acknowledged RA is not a new concept (cf. Hanway and Evans, 2000), despite this, a 73 
number of challenges continue to impede its wider use. When applying RA to fill a 74 
toxicological data gap, a number of fundamental questions repeatedly arise (Schultz et al., 75 
2014), including:  76 
- Is it possible to form a robust group of chemicals (often referred to as a chemical 77 
category) which includes the target chemical? 78 
- Is the category relevant to fill a data gap considering the toxicology of the endpoint 79 
under assessment? 80 
- Are there appropriate toxicology studies of sufficiently high quality for the source 81 
chemical(s) to allow a meaningful RA? 82 
- Are the uncertainties defined and are they acceptable in order to use the read across 83 
prediction(s) to fill the data gap(s) for a specific regulatory purpose? 84 
To address these questions and others, a flexible strategy for developing and reporting a 85 
repeated-dose RA prediction was devised and applied in the case studies (Schultz et al., 86 
2015). Briefly, this strategy focuses on the two main elements of a RA, namely:  87 
- assessment of the similarity between source and target substance(s) and,  88 
- assessment of the uncertainties in the RA process and ultimate prediction.  89 
It is worth noting the publication of this strategy predates ECHA’s Read-Across Assessment 90 
Framework (RAAF) (ECHA, 2015). Regardless of process, the standards for accepting a RA 91 
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prediction are likely to vary little, as the aim of a RA is to provide a prediction(s) that is 92 
(more or less) equivalent to that which would be obtained from the standard animal study. 93 
In order to address at least some of the above questions, and to determine the suitability of 94 
RA to fill data gaps for repeated-dose toxicity (focussing on the oral route of exposure to the 95 
rat), Berggren et al. (2015) recommended that a series of case studies be conducted for the 96 
most likely RA scenarios. An additional recommendation was that each case study be 97 
evaluated in a two-step process. The initial step was to be a “traditional” RA using 98 
established in vivo data supplemented, as applicable, with conventional in vitro and classic 99 
structure-activity relationship information. The second iteration was to be a RA with the 100 
initial information and data supplemented with “New Approach Methodology” (NAM) data 101 
from high-throughput screening (HTS), novel in vitro methods and/or toxicogenomic assays. 102 
Following an external review process, the findings of four case studies for the filling of data 103 
gaps for repeated-dose toxicity using RA have been published, covering a variety of RA 104 
scenarios. The RA case studies were all for 90 day rat repeated-dose toxicity and explored: 105 
i) The suitability of 2-propen-1-ol as a read-across analogue for other short chain 106 
primary and secondary β-olefinic alcohols on the basis of similarity in metabolic 107 
transformation (Przybylak et al., 2017). 108 
ii) The use of data for short-chain mono-alkylphenols to fill data gaps for other 109 
mono-alkylphenols on the basis of similarity in toxicokinetics and toxicodynamics 110 
(Mellor et al., 2017). 111 
iii) An investigation of saturated 1-alkanols presumed to be of low toxicity and 112 
varying in toxicokinetics as a results of alkyl chain (assuming no branching on the 113 
alkyl chain) (Schultz et al., 2017a). 114 
iv) Consideration of 2-alkyl-1-alkanols where branching of the alkyl chain may affect 115 
RA for low toxicity chemicals (Schultz et al., 2017b). 116 
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 117 
Whilst the reader is encouraged to examine the case studies (Przybylak et al., 2017; Mellor et 118 
al., 2017; Schultz et al., 2017a; Schultz et al., 2017b), a summary of the findings is presented 119 
in Table 1. As summarised in Table 1, the four RA case studies were evaluated in terms of 120 
the robustness of arguments and the uncertainty associated with the different elements of the 121 
category formation. It is important to note that these case studies were not performed for the 122 
purpose of regulatory submission, but to investigate the process of RA and how it could be 123 
improved. As such they provide a rich source of potential knowledge and learning for the 124 
development and direction of future RA studies. It is also acknowledged that various other 125 
RA case studies have been published (Blackburn et al., 2011; de Abrew et al., 2016; van 126 
Ravenzwaay et al., 2016) and, whilst they have not been evaluated explicitly in this 127 
investigation as they are based on different endpoints and approaches, there has been implicit 128 
learning from these. 129 
 130 
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Table 1. Summary of the main findings of the read-across case studies for repeated dose chronic toxicity 131 
Chemical 
Category and 
Reference 
Key Features of Similarity Amongst All 
Compounds in the Category in Terms of 
Structure, ADME and Toxicity 
Summary of Weight(s) of 
Evidence To Support Read-
Across for the Category 
Conclusion Regarding 
Uncertainty 
    
n-alkanols; C5-
C13 (Schultz et 
al 2017a) 
 Single OH group; C5-C13 chain length, straight-
chain hydrocarbon scaffolding. 
 Absorbed from the gut; distributed in the blood 
in solution; first pass metabolism leads mainly 
to the corresponding carboxylic acid; subsequent 
mitochondrial β-oxidation to CO2 
 No systemic toxicity; no chemical reactivity or 
receptor-mediated interactions; nonpolar 
narcosis is a probable mode-of action. 
Chemistry: High 
Toxicokinetics: Medium 
Toxicodynamics: 
   In vivo: High 
   In vitro: High 
Overall: High   
Same as performing an 
OECD TG 408 test 
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2-alkyl-1-
alkanols; C5-
C13 (Schultz et 
al 2017b) 
 Single OH, C5-C13 chain length with a 2-
position C1-C3 hydrocarbon scaffolding. 
 Absorbed from the gut; distributed in the blood 
in solution; first past metabolism leads mainly to 
glucuronidation; subsequent elimination in the 
urine.  
 No systemic toxicity; no chemical reactivity or 
receptor-mediated interactions; probable mode-
of action is nonpolar narcosis. 
Chemistry: High 
Toxicokinetics: Medium 
Toxicodynamics: 
   In vivo: High 
   In vitro: High 
Overall: 
   2-ethyl- and 2-propyl-1 
alkanols: High 
   2-methyl-1-alkanols: 
Medium 
Same as performing an 
OECD TG 408 test 
β-olefinic 
alcohols; C3 to 
C6 (Przybylak 
et al 2017) 
 Single OH group; C3-C6 hydrocarbon 
scaffolding with β-vinylic moiety. 
 Absorbed from the gut; distributed in the blood 
in solution; first past metabolism leads to the 
corresponding α, β-unsaturated aldehyde or α, β-
unsaturated ketone. 
Chemistry: High 
Toxicokinetics: Medium 
Toxicodynamics: 
   In vivo: Medium 
   In vitro: High 
Overall: 
Straight-chain β -olefinic 
alcohols: same as 
performing an OECD TG 
408 test; 
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 The corresponding α, β-unsaturated derivatives 
are the definitive electrophilic toxicants; likely 
mode-of action is Michael addition; in vivo 
potency is related to relative thiol reactivity. 
   Straight-chain β-olefinic 
alcohols: high 
   Branched-chain β -olefinic 
alcohols: medium 
branched-chain β -olefinic 
alcohols: 2-propen-1-ol is 
the worst case scenario  
mono-
substituted 
alkyl phenols; ≤ 
C4 substituent 
(Mellor et al 
2017) 
 Single (≤ C4) alkyl group on a phenolic ring 
scaffolding. 
 Absorbed from gut, distributed in the blood in 
solution, first past metabolism leads mainly to 
Phase II conjugation to glucuronides and 
sulphates; excreted in the urine.  
 No systemic toxicity; no chemical reactivity; no 
relevant receptor-mediated interactions; 
probable mode-of action is polar narcosis. 
Chemistry: High 
Toxicokinetics: Medium 
Toxicodynamics: 
   In vivo: High 
Overall: High   
Same as performing an 
OECD TG 408 test 
 132 
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 133 
1.2. The aim 134 
The present paper recapitulates with examples the lessons learned from the recent series of 135 
case studies which illustrate specific issues associated with modern-day toxicological RA of 136 
repeated dose toxicity. The case studies cited have the advantage of having undergone 137 
external review prior to publication. We believe this summary of lessons has the potential of 138 
furthering the acceptance of RA predictions, especially for predictions of NOAELs from 139 
repeated-dose toxicity studies. 140 
 141 
2. Methods and Materials 142 
The findings reported here build on previous analyses, starting with guidance (ECETOC, 143 
2012; ECHA, 2009, 2011; OECD, 2007, 2011, 2014a, 2015) on grouping of chemicals and 144 
RA as well as other publications in this area (Ball et al., 2014, 2016; Cronin et al. (2013); 145 
Blackburn and Stuard, 2014; Patlewicz et al., 2013a, 2013b, 2014, 2015; Patlewicz and 146 
Fitzpatrick, 2016). 147 
As stated in the introduction, the case studies from which the findings in this paper were 148 
arrived at were Przybylak et al. (2017), Mellor et al. (2017) and Schultz et al. (2017a, 2017b). 149 
Each case study is consistent with RA principles previously described (e.g., ECHA, 2013a, 150 
2013b; OECD, 2015; Schultz et al., 2015). These four case studies, while developed by an 151 
iterative effort of their authors, were extensively reviewed by various independent experts. 152 
 153 
3. Lessons Learned 154 
RA case studies have crucial evidentiary value in regulatory toxicology. Amongst other 155 
things, they provide a means of illustrating how it may be possible to move from chemical-156 
12 
 
by-chemical assessments based on animal testing to assessments by interpolation within a 157 
toxicologically-relevant and mechanistically plausible chemical category. In the context of 158 
this paper, case studies provided an opportunity to benchmark some of the lessons learned or 159 
confirmed to use RA in a regulatory context. 160 
3.1. Today’s read-across 161 
Early approaches to RA, e.g. identification of analogues with varying chain lengths (Hanway 162 
and Evans, 2000; Patlewicz and Fitzpatrick, 2016) are increasingly being seen as simplistic 163 
and trivial, especially for regulatory use. Today “chemical similarity” means more than 164 
proving similarity in chemistry; it requires the category formation and RA process to be 165 
transparent, reproducible and clearly documented. Specifically, key principles of biological, 166 
as well as chemical, similarity need to be supported, where possible, by data and scientific 167 
evidence. To improve the acceptability of any RA estimate, there is a need to justify the 168 
prediction by explaining in a scientifically defensible manner how it was derived and why it 169 
is justifiable for the intended purpose (e.g., priority setting, risk assessment). 170 
Analysis of the four RA case studies confirmed that transparency should take the form of 171 
reporting, in appropriate detail, all relevant data used both to establish similarity arguments 172 
and the read across value. Such transparency can be accomplished in either a narrative 173 
presentation or in tabular form – with advantages and disadvantages to both. The latter, while 174 
leading to a shorter document, often requires the assessors to identify key information and/or 175 
data from the tables. The former often leads to a longer document where, however, the same 176 
information may be repeated. 177 
In order to accept a RA prediction(s), the assessor needs to have confidence in the accuracy 178 
of the prediction. This confidence can be attained in several ways. One method is to provide 179 
sufficient information and data in the RA documentation such that the prediction can be 180 
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reproduced. To meet these requirements for transparency and reproducibility, clear 181 
documentation, especially by following a template or strategy (e.g., OECD 2015; Schultz et 182 
al., 2015, ECHA, 2015), is extremely helpful. Such methodologies provide “check lists” of 183 
the types of information critical to establishing confidence. As part of the “New Approach 184 
Methodologies” workshop one of the four cases studies on which this article is based was 185 
assessed, independently, within the context of the ECHA RAAF (ECHA, 2015), it was clear 186 
that the RAAF provided a structured means of determining the confidence in a RA. Further, 187 
this leads to the possibility of developing a template for developing RA arguments for 188 
regulatory use from the criteria detailed in the RAAF.  189 
3.2. Uncertainties in RA 190 
Sources of uncertainty in RA must be identified and addressed. Uncertainty includes a variety 191 
of elements which can be separated into:  192 
- the uncertainty associated with the concept and completeness of the RA argument 193 
and,  194 
- the uncertainty associated with the similarity justification (Schultz et al., 2015). 195 
There are uncertainties associated with the basic tenet of the RA (i.e., the results of in vivo 196 
study/ies of the source substance(s) which are to be read across to the target analogue). The 197 
case studies confirmed that a key issue in any RA argument is to lower the overall uncertainty 198 
to an acceptable level; without high quality data for at least one source substance, it is not 199 
possible to conduct RA. With regard to risk assessment, the required level of uncertainty in 200 
the RA prediction should be similar to that associated with an appropriate in vivo test (e.g., 201 
OECD TG 408) and was assessed in the context of the template provided by Schultz et al. 202 
(2015). For other regulatory applications (e.g., screening and priority setting), higher levels of 203 
uncertainty may be acceptable. Thus, the first source of uncertainty that must be addressed is 204 
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related to the quality of the read across data (e.g., 90-day oral repeated-dose no observable 205 
adverse effect level (NOAEL)). Analysis of the data considered in the case studies indicated 206 
that such uncertainty may be best addressed using data from well-designed studies where the 207 
phenotypic expressions at the lowest observable adverse effect level (LOAEL) are reported 208 
e.g. for repeated-dose toxicity, a study which followed OECD TG 408. The quantity of in 209 
vivo data also affects uncertainty. It is intuitive that reading across from multiple source 210 
substances (i.e., a category approach), as in the 1-alkanol case study (Schultz et al., 2017a), 211 
has less uncertainty than reading across from one source substance (i.e., an analogue 212 
approach), as in the -olefinic alcohol case study (Przybylak et al., 2017). Uncertainty within 213 
a RA is reduced by interpolation within a category bracketed by experimental in vivo data, as 214 
illustrated in the alkyl-phenol case study (Mellor et al., 2017), as opposed to extrapolation 215 
from data for one structural extreme of a category to another, as described in the 2-alkyl-1-216 
alkanol case study (Schultz et al., 2017b). 217 
Uncertainty associated with the similarity arguments is based on two interrelated rationales. 218 
Firstly, that the target and source substances are “sufficiently similar” to be toxicologically 219 
relevant. Secondly, “differences in similarity” are not relevant to the endpoint under 220 
consideration (Schultz et al., 2015). Confirming the latter was found to be a problematic task 221 
in the case studies. For example, in the 2-alkyl-1-alkanol case study (Schultz et al., 2017b), 222 
the authors believe the 2-methy-derivatives are “sufficiently similar” to the 2-ethyl- and 2-223 
propyl-derivatives; however,  the lack of in vivo repeated-dose toxicity data for a 2-methyl-224 
derivative made it difficult to say with confidence that the structural difference does not 225 
preclude the inclusion of the methyl-substituted derivatives in a category defined with 226 
experimental data for 2-ethyl- and 2-propyl-substituted primary alcohols. 227 
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The assessment of uncertainty associated with a similarity justification is shown to include 228 
consideration of all information supporting the similarity argument. For example, for 229 
repeated-dose toxicity, the four case studies all revealed that not only are similarities in 230 
structure and chemical properties required, but also similarities associated with toxicokinetic 231 
and toxicodynamic properties. As such, data from in vitro assays, including new-methods 232 
(e.g., HTS) and in silico tools, often provide critical information needed to strengthen 233 
mechanistic and toxicodynamic similarity rationales. Establishing toxicokinetic similarity 234 
(i.e., ADME properties), especially for metabolism and metabolic rates, is often the driver of 235 
the overall uncertainty (Ball et al., 2014; Hand et al., 2017) and was shown to be a key factor 236 
in the separation of the saturated aliphatic primary alcohols into two categories for RA (see 237 
Schultz et al., 2017a, 2017b). 238 
3.3. Toxicological meaningful categories for repeated-dose toxicity 239 
Forming a toxicological meaningful category for longer-term hazards such as repeated-dose 240 
toxicity becomes a daunting task (Berggren et al., 2015). Data reported for repeated-dose 241 
hazards are elaborate, typically based on a defined vocabulary list of possible symptoms. For 242 
example, ToxRefDB (US EPA, 2008) includes in vivo data for 309 structures and lists more 243 
than 22,000 vocabulary items; whilst some are quantitative, most are qualitative (e.g., 244 
positive versus negative; increase versus decrease). Symptoms reported include clinical 245 
chemistry, haematological and urinalysis, as well as gross and microscopic pathological 246 
findings. It is intuitive that these symptoms cannot all be related to the same in vivo effect. 247 
Since exposure for chronic effects is over a longer duration (e.g., 28 days or longer in the 248 
case of repeat-dose toxicity), the in vivo damage is likely to be cumulative. Thus, the reported 249 
values such as a NOAEL or LOAEL vary as to incidence, target organ, severity etc. (Martin 250 
et al., 2009). Whilst limitations to forming a toxicologically meaningful category for 251 
quantitative RA include the availability of suitable in vivo data to be read across and the lack 252 
16 
 
of toxicologically-relevant in vitro or NAM data to support mechanistic plausibility, the 253 
major limitation to using RA for repeated dose endpoints is often the lack of toxicokinetics 254 
understanding and data. 255 
3.4. Mechanistic plausibility 256 
While not always possible, stating and documenting mechanistic plausibility improves the 257 
likelihood of a RA prediction being accepted. This is especially true if mechanistic 258 
plausibility can be linked to a mode of toxic action or an adverse outcome pathway (AOP) 259 
(Ellison et al., 2016). An adverse outcome pathway is a description of plausible causal 260 
linkages, illustrating how a molecular initiating event may lead to the key biochemical, 261 
cellular, physiological behavioural etc. responses resulting in an apical effect; it thus 262 
characterises the biological cascade across the different levels of biological organisation 263 
(OECD, 2013; OECD 2014b).  264 
As seen with the case studies for n-alkanols and 2-alkyl-1-alkanols (Schultz et al., 2017a; 265 
2017b), even incomplete mechanistic understanding in the form of presumptive AOPs has 266 
value in establishing toxicological meaningful categories. Moreover, presumptive AOPs 267 
provide a means of linking ex vivo, in vitro and in chemico effects to the apical in vivo 268 
endpoint of interest. As demonstrated in the -olefinic case study (Przybylak et al., 2017), 269 
confidence in mechanistic plausibility can be increased by the use of toxicologically-relevant 270 
alternative methods data. In the latter case, the in vivo data for a single source substance are 271 
supported by ex vivo data for five category members, including the source substance, as well 272 
as in chemico data for 16 category members, again including the source substance. In this 273 
way, NAM data have contributed to mechanistic understanding and hence supported the 274 
hypothesis of category membership.  275 
3.5. Endpoint specificity 276 
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Predictions from RA are more likely to be acceptable when undertaken on an endpoint-by-277 
endpoint basis. The case studies for 1-alkanols and 2-alkyl-1-alkanols (Schultz et al., 2017a, 278 
2017b) demonstrated that for acute oral rat toxicity, measured as the LD50 (mg/kg), the two 279 
alkanols sub-classes form a single category. Specifically, there is a similar mode of toxic 280 
action, similar Toxicity Forecaster database (ToxCast) molecular fingerprints and similar 281 
experimental LD50 values of 3000 mg/kg bw. Thus, both sub-classes belonged to the same 282 
category for rat acute oral toxicity and experimental results (i.e., the LD50 value) can be read 283 
across to untested analogues with acceptable uncertainty. In contrast, for read-across of 90-284 
day oral repeated-dose toxicity endpoint, expressed as the NOAEL values (mg/kg bw/d), the 285 
n-alkanols and the 2-alkyl-1-alkanols formed two separate categories. Specifically, whilst 286 
similar in mode of toxic action with similar ToxCast results, the NOAEL values (1000 and 287 
125 mg/kg bw/d for n-alkanols and the 2-alkyl-1-alkanols, respectively) are dissimilar. In 288 
this case read across for rat oral repeated-dose toxicity can be achieved with acceptable 289 
uncertainty only after appropriate sub-categorisation into the different chemical sub-classes 290 
(see Schultz et al., 2017a, 2017b). 291 
3.6. Rationale for grouping substances 292 
RA approaches have been developed on an over-arching rationale for grouping substances 293 
based on molecular structure and chemical properties (Cronin et al., 2013). The case studies 294 
have, however, demonstrated that these similarities in chemistry alone are often not sufficient 295 
to justify a RA prediction. This is especially the case for sub-chronic and chronic health 296 
effects, where multiple dosing may lead to different toxicokinetic and toxicodynamic 297 
properties (Schultz et al., 2015). Further information that is often required typically includes 298 
that related to toxicokinetic and toxicodynamic properties  e.g., metabolism, clearance, 299 
mechanistic plausibility etc. The case studies for the 1-alkanols and 2-alkyl-1-alkanols 300 
(Schultz et al., 2017a, 2017b) demonstrated that the over-arching rationale for grouping is the 301 
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same, i.e. highly similar chemistry and similar mechanistic plausibility in the form of an 302 
anaesthetic-like mode of toxic action. Despite this, key toxicokinetics parameters are 303 
different. Specifically, whilst absorption and distribution are highly similar for both groups of 304 
saturated alcohols, metabolism and elimination are different. 1-Alkanols, such as 1-octanol, 305 
are excreted mainly (>90%) as CO2, and to a lesser extent as n-glucuronide in the urine 306 
(Schultz et al., 2017a). In contrast, experimental data reveal that the major pathways of 307 
metabolism of branched saturated alcohols, such as 2-alkyl-1-alkanols, lead to conjugation 308 
with glucuronic acid. In addition, there is often oxidation of the alcohol group, as well as 309 
side-chain oxidation (Schultz et al., 2017b). Thus, whilst there is structural similarity within 310 
the alkanols, sub-categorisation is required to facilitate efficient RA. 311 
3.7. Weights-of-Evidence (WoE) 312 
The consideration of all relevant information used to undertake and support a RA can be 313 
achieved through Weight(s)-of-Evidence (WoE). Clearly, increased WoE has the possibility 314 
to reduce uncertainties both in relation to similarity justifications and the completeness of the 315 
read-across argument. The increased WoE can take the form of using different types of in 316 
vivo information and data (Schultz et al., 2017a, 2017b) or using in vitro and/or in chemico 317 
information and data (Mellor et al., 2017; Przybylak et al., 2017) – as such it can be seen as 318 
an extension of the support that can be provided for mechanistic plausibility.  319 
The case study for 1-alkanols (Schultz et al., 2017a) demonstrated that uncertainty associated 320 
with RA predictions was reduced by increasing WoE through the addition of information 321 
from in vivo data. Specifically, the uncertainty associated with the RA of a 90-day rat oral 322 
repeated-dose NOAEL may be reduced following the inclusion of in vivo information from 323 
derivatives tested with a related protocol (e.g., OECD TG 408 vs OECD TG 422 studies) 324 
where qualitative and quantitative similarity are established. In addition, the -olefinic 325 
alcohols case study (Przybylak et al., 2017), demonstrated that non-animal test data increase 326 
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the WoE for the RA justification through the results from toxicologically-relevant alternative 327 
methods. This increase in WoE can be in the form of relevant data from both the source and 328 
target chemicals, as well as relevant data for other substances within the applicability domain. 329 
The overall WoE may also be improved by having information for chemicals that may, in 330 
terms of mechanistic plausibility, be considered to be outside the category. The -olefinic 331 
alcohol case study (Przybylak et al., 2017), demonstrated that saturated alcohols, which were 332 
outside the domain of the RA, exhibited test results for ex vivo and in chemico endpoints 333 
markedly different from results for -olefinic alcohols. Thus, the most likely mechanism of 334 
toxic action (i.e., alcohol dehydrogenase mediated metabolism leading to a Michael-acceptor 335 
electrophile) is limited to -olefinic alcohols. These consistent differences also add to the 336 
WoE. 337 
3.8. Using New Approach Methodology  data 338 
Relevant and reliable NAM data are useful in reducing the uncertainty in toxicodynamics and 339 
improve mechanistic understanding (ECHA, 2016). The use of data from NAMs will assist in 340 
the acceptance of a “low/no toxic” RA prediction where a higher level of certainty is likely to 341 
be required (Schultz et al., 2017a).  342 
In silico methods are the easiest, most rapid and often the cheapest NAM and are appealing 343 
as a good alternative first approach. However, they are useful only when there is confidence 344 
that in silico models are of high quality and have been applied correctly.  In all four case 345 
studies, in silico models were used to establish similarities in physico-chemical properties, as 346 
profilers for possible toxicophores, and to examine potential metabolic similarity. 347 
Several of the case studies demonstrated that HTS (i.e., ToxCast results) can assist in 348 
establishing the most likely pathway leading to an in vivo adverse outcome. Typically, these 349 
20 
 
data were used to support a mode of toxic action developed from non-mammalian data or a 350 
presumptive AOP (see Schultz et al., 2017a; Mellor et al., 2017). 351 
In vitro assays which express a particular pathway and associated pathologies were found to 352 
be useful to link relevant in vitro data to the apical endpoint predicted in the RA. In this way, 353 
mechanistically fit-for-purpose data can reduce uncertainty and increase the WoE. For 354 
example, in the -olefinic alcohol case study (Przybylak et al., 2017), metabolism is 355 
presumed to lead to derivatives that cause oxidative stress thus leading to narcosis and 356 
apoptosis that, in principle, lead to in vivo fibrosis. The incorporation of NAMs data into RA 357 
arguments allowed for the addition of relatively rapid and inexpensive hypothesis-driven 358 
testing and evaluation. This has the advantage of performing targeted, rather than universal, 359 
tests. 360 
In the near future, new in vitro systems based on multiple cell-to-cell interactions and fit-for-361 
purpose based mechanistic reasoning are likely to add confidence to RA predictions. For 362 
example, 3D co-culture systems, such as those reported by Wink et al. (2014) and 363 
Ramaiahgari et al. (2014) consisting of a HepG2 BAC-GFP reporter system, or that of Leite 364 
and co-workers (2015) consisting of hepatic organoids (of human hepatocyte-like cells 365 
(HepaRG) and primary human hepatic stellate cells) were used to measure stress response 366 
activation and fibrosis as proposed in the -olefinic alcohol case study (Przybylak et al., 367 
2017). 368 
3.9. Size of category  369 
The development and evaluation of the case studies also highlighted the balance required 370 
between reducing uncertainty by restricting the size of a category i.e. its applicability domain 371 
and making it a meaningful size. At the extremes category definition may be very broad e.g. 372 
aliphatic alcohols, or highly specific restricting it to a very small number of members. The 373 
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case studies demonstrated that, in reality, neither is ideal for RA. Broad definitions of 374 
applicability domains often do sharply increase the uncertainty associated with RA 375 
predictions for some substances within the domain, whilst very narrow definitions make 376 
decrease the practical utility and make it more difficult to build up a body of evidence.  For 377 
example, in the initial RA evaluation of the -unsaturated alcohols (Przybylak et al., 2017), a 378 
broader category including the -acetylenic alcohols (e.g., 1-propyn-3-ol) was considered. 379 
Subsequently, due to toxicokinetic uncertainty, these derivatives were eliminated from 380 
consideration which had the effect in decreasing uncertainty, but reduced the breadth of the 381 
applicability domain of the category. Furthermore, in the β-olefinic alcohol case study, the 382 
single source substance, allyl alcohol, is unique and is effectively a category on its own. 383 
While all ,-unsaturated carbonyl compounds derived from hepatic metabolism of primary 384 
and secondary -olefinic alcohol readily react with glutathione (Przybylak et al., 2017), there 385 
is less uncertainty associated with straight-chain alcohols (e.g., 1-alken-3-ols and 2-alken-1-386 
ols) than with branched alcohols (2-methyl-2-alken-1-ols, 3-methyl-2-alken-1-ols).  387 
Accordingly, as noted by Przybylak et al. (2017), uncertainty may be better addressed via 388 
sub-categorisation. In the 2-alkyl-1-alkanol study (Schultz et al., 2017b), there is greater 389 
uncertainty associated with the 2-methyl-substituted derivatives. Whilst they are considered 390 
within the domain of the RA, there are no in vivo experimental data supporting their 391 
inclusion; thus, greater uncertainty.  392 
 393 
4. Discussion 394 
A basic understanding of what a RA to fill data gaps for hazard and / or risk assessment 395 
should look like, to garner regulatory acceptance, is rapidly taking shape (Teubner and 396 
Landsiedel, 2015; Ball et al., 2016). As noted by OECD, the lessons learned from the 397 
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cooperative review of case studies on grouping methods (such as RA) have increased 398 
experience in the application of these approaches (OECD, 2016). However, it has also been 399 
recognised that more case studies are needed for developing general guidance (OECD, 2016). 400 
The evaluation of the series of case studies on which this article is based has indicated that 401 
the acceptability of a RA prediction is often dependent on the evaluator’s sense of confidence 402 
in the documentation and evidence provided. High confidence is associated with RAs when 403 
there is strong proof that the prediction is valid i.e., low uncertainty.  The case studies have 404 
shown that improvement in the acceptance of RA predictions is accomplished in several 405 
ways. Firstly, high quality in vivo endpoint data are essential to anchor any RA; higher 406 
confidence is linked to qualitative and quantitative consistency with more than a single 407 
source substance. Secondly, it is essential to establish the adequacy and reliability associated 408 
with the underlying hypothesis of chemical and / or biological similarity. Higher confidence 409 
is linked to arguments built on toxicokinetics and toxicodynamics, support by an assessment 410 
of similarities in chemistry rather than being driven by chemical similarity alone. Thirdly, the 411 
depth and breadth of supporting information is important; higher confidence is linked to 412 
studies with increased WoE which is typically provided by information form non-animal 413 
methods. Fourthly, higher confidence is associated with strong evidence of mechanistic 414 
plausibility. Finally, higher confidence is associated with supporting evidence provided by 415 
hypothesis-based testing, especially with fit-for-purpose in vitro and in chemico assays. The 416 
latter come with the caveat that these sources of information meet reliability issues (e.g., 417 
repeatability and reproducibility) often need for regulatory acceptance. 418 
4.1. Summary 419 
RA arguments are best established:  420 
1. in a context-dependent manner (one size does not fit all),  421 
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2. on one-to-one (analogue) or many-to-one (category) basis rather than a one to many 422 
or a many to many arguments, and  423 
3. on the basis of a single well-defined endpoint (e.g., time, species, route of exposure, 424 
etc.). 425 
In conclusion, addressing uncertainty in a RA prediction is central to regulatory acceptance. 426 
For some endpoints (e.g., ecotoxicity, skin sensitisation, genotoxicity), useful frameworks are 427 
available, whilst for other endpoints, especially those related to chronic health, further work 428 
is needed. 429 
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